Chemicalinfo Chemlink Pharm-Chem Net

Brazil Rejects Patent On An Essential AIDS MedicineThe Brazilian Patent Office has rejected a patent application by Gilead on the drug tenofovir disoproxil fumarate (TDF), in a move that could increase access to a key HIV/AIDS medicine across the d...

"Shelved" Antihistamine Shows Promise in Alzheimer's Disease - Dimebon By Caroline CasselsMedscape Medical News May 16, 2007 (Chicago, Illinois) - A largely forgotten antihistamine, first used in Russia more 30 years ago but shelved ...

「退役的」抗组织胺 Dimebon 看似对阿兹海默氏症有效作者：Caroline Cassels 出处：WebMD专业新闻May 16, 2007(伊利诺州芝加哥) — 一个在30年前首次在俄罗斯使用、目前被大众遗忘的抗组织胺，显示出对轻微到中度的阿兹海默氏症(AD)有疗效。Dimebon (Medivation，San Francisco，CA)用于183名AD病患的一年期随机安慰剂控制试验，最近在美国神经医学会第60届年会中发表，显示服用此药物者在认知功能、记忆力、日常生...

Gleevec(imatinib mesylate) Receives FDA Priority Review As First Therapy To Reduce Recurrence Of Gastrointestinal Stromal Tumors After SurgerySeptember 7th, 2008 by allsochNovartis announced that Gleevec® (imatinib mesylate) tablets has been gr...

Brazil rejects Gilead patent for HIV/AIDS drug Viread (Tenofovir DF)04 September 2008 The patent application had been opposed by a coalition of Brazilian nongovernmental organizations (NGOs) and a government pharmaceutical laboratory, and represen...

Thai Government Deals Patent Blow to Big Pharma’s Cancer Drug Monopoly (NaturalNews) Health Minister Chaiya Sasomsap said that the government of Thailand will override the patents on three cancer drugs, after pressure from health activists a...

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Roche vs Cipla: Will the Real Price of "Tarceva" Please Show Up?Last Thursday, Arun Jaitley finally wound up his arguments on behalf of Cipla. A very impressive performance and I can see why Cipla won relatively easily at the first insta...

FDA MedWatch - July 2008 Drug Safety-Related Labeling Changes for 35 Drugs Now Available on Web  The July 2008 posting includes 35 drug products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARN...

The targeted agent Sutent® (sunitinib) provides superior quality of life compared with interferon alfa for patients with advanced renal cell carcinoma (RCC). These results were recently published in the August 1, 208 issue of Journal of Clinical Oncology.